カテゴリー： 世界, 医療/バイオ, visiongain

世界の呼吸器用吸入器市場2023年～2033年

【英語タイトル】Respiratory Inhalers Market Report 2023-2033 : Forecasts by Product Type (Standard Pressurised Metered-Dose Inhalers, Pressurised Metered-dose Inhalers, Metered-Dose Inhaler with a Spacer, Dry Powder Inhalers, Soft Mist Inhalers, Others), by Drug Class (ICS, SABA+ICS, SABA, LABA, LAMA, ULABA, SABA+SAMA, LABA+LAMA+ICS, SAMA, Others), by Mode of Operation (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices, Others), by Indication (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

visiongainが出版した調査資料（VGA23FB021）・商品コード：VGA23FB021
・発行会社（調査会社）：visiongain
・発行日：2022年12月13日
・ページ数：354
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Sigle User（1名様閲覧用、1年間、印刷不可）GBP3,950 ⇒換算￥750,500見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）GBP6,950 ⇒換算￥1,320,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界の呼吸器用吸入器市場規模が2033年までに年平均8.02%で成長すると予測しています。本レポートは、呼吸器用吸入器の世界市場を徹底調査し、レポート概要、エグゼクティブサマリー、市場動向、製品種類別（標準定量吸入器、スペーサー付き定量吸入器（MDI）、ドライパウダー吸入器（DPI）、ソフトミスト吸入器、その他）分析、薬物クラス別（ICS、SABA、LABA、LAMA、その他）分析、疾患別（喘息、慢性閉塞性肺疾患（COPD）、肺動脈性肺高血圧症、その他）分析、動作モード別（手動吸入器、デジタル式吸入器、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報などの内容を作成しました。本書には、3M Health Care、AptarGroup, Inc.、AstraZeneca、Boehringer Ingelheim International GmbH、Cipla Inc.、GF Health Products, Inc.、GSK plc、Koninklijke Philips N.V.、Medisana GmbH、Merck & Co., Inc.、Novartis AG、OMRON Corporation、Recipharm ABなどの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界の呼吸器用吸入器市場規模：製品種類別
- 標準定量吸入器の市場規模
- スペーサー付き定量吸入器（MDI）の市場規模
- ドライパウダー吸入器（DPI）の市場規模
- ソフトミスト吸入器の市場規模
- その他製品の市場規模
・世界の呼吸器用吸入器市場規模：薬物クラス別
- ICSの市場規模
- SABAの市場規模
- LABAの市場規模
- LAMAの市場規模
- その他薬物クラスの市場規模
・世界の呼吸器用吸入器市場規模：疾患別
- 喘息用吸入器の市場規模
- 慢性閉塞性肺疾患（COPD）用吸入器の市場規模
- 肺動脈性肺高血圧症用吸入器の市場規模
- その他疾患の市場規模
・世界の呼吸器用吸入器市場規模：動作モード別
- 手動吸入器の市場規模
- デジタル式吸入器の市場規模
- その他動作モードの市場規模
・世界の呼吸器用吸入器市場規模：地域別
- 北米の呼吸器用吸入器市場規模
- ヨーロッパの呼吸器用吸入器市場規模
- アジア太平洋の呼吸器用吸入器市場規模
- 中南米の呼吸器用吸入器市場規模
- 中東・アフリカの呼吸器用吸入器市場規模
・企業情報

The Respiratory Inhalers Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing R&D Expenditure by Pharmaceutical and Biotechnology Companies Driving Market Growth
As the demand for greater precision in drug delivery grows, respiratory inhaler devices, particularly among asthmatics and those suffering from chronic obstructive pulmonary disease, are becoming more popular. Because they have a decreased degree of immunity to chronic and pulmonary diseases, an increasing percentage of senior people utilise inhalers. Respiratory inhalers include complementary spacers or holding chambers to reduce the number of debris deposited in the mouth and throat. The market for respiratory products is expected to grow even more in light of the proposed shift to home healthcare.

One of the major digital platforms on which pharma and digital companies collaborate for the management of respiratory diseases is the smart inhaler market. In recent years, government organizations have been concerned about the rising death rates associated with respiratory diseases such as asthma and COPD. Government and regulatory agencies have implemented new guidelines in recent years that will significantly impact the market growth of smart inhalers. Increasing numbers of organizations are integrating digital technologies into their devices in an effort to improve medication management efficiency. The HeroTracker Sense application was launched by Aptar Pharma in April 2023, for example. Pressurized metered dose inhaler (pMDI) can now be converted into a smart connected health device through the use of this new digital respiratory health solution.

High Cost of Inhalers Likely to Challenge Market Growth
Despite the increased prevalence of asthma worldwide, including in emerging markets such as Asia and developed areas such as North America, several barriers to the acceptance of these therapies exist. Inhalers are frequently regarded as the primary treatment for asthma, which is one of the major issues limiting market growth. According to the NCBI study, the CDC will spend approximately 49 billion in 2020, with Medicare covering only 51% of the COPD cost burden. As a result, the price of Advair, a critical asthma medication, has risen to US$648.8 in 2023, up from US$496.0 in 2013.

In addition to the high cost of drugs, underdiagnosis of asthma has been a key issue restricting market expansion. Asthma underdiagnosis leads to lower clinical outcomes for people who are unable to take the right asthma medicines to treat their medical condition. A lack of awareness and perception of asthma in the community, poor access to health care, strained health systems, the absence of diagnostic tests, including spirometry, a lack of training among health care providers, and a lack of non-implementation of asthma guidelines are all factors that contribute to underdiagnosis of asthma.

What Questions Should You Ask before Buying a Market Research Report?
• How is the respiratory inhalers market evolving?
• What is driving and restraining the respiratory inhalers market?
• How will each respiratory inhalers submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each respiratory inhalers submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading respiratory inhalers markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the respiratory inhalers projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of respiratory inhalers projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the respiratory inhalers market?
• Where is the respiratory inhalers market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the respiratory inhalers market today, and over the next 10 years:
• Our 354-page report provides 126 tables and 184 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the respiratory inhalers market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising respiratory inhalers prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product Outlook
• Standard Pressurized Metered-Dose Inhalers
• Pressurized Metered-dose Inhalers (pMDI)
• Metered-Dose Inhaler with a Spacer
• Dry Powder Inhalers
• Soft Mist Inhalers
• Other Inhaler Type

Drug Class
• ICS
• SABA+ICS
• SABA
• LABA
• LAMA
• ULABA
• SABA+SAMA
• LABA+LAMA+ICS
• SAMA
• Other Class

Mode of Operation
• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices
• Other Mode Of Operation

Indication
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Pulmonary Arterial Hypertension (PAH)
• Others Respiratory Disease

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Respiratory Inhalers Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• 3M Health Care
• AptarGroup, Inc.
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• GF Health Products, Inc.
• GSK plc
• Koninklijke Philips N.V.
• Medisana GmbH
• Merck & Co., Inc.
• Novartis AG
• OMRON Corporation
• Recipharm AB
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

Overall world revenue for Respiratory Inhalers Market, 2023 to 2033 in terms of value the market will surpass US$45.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Respiratory Inhalers Market, 2023 to 2033 report help you?
In summary, our 350+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Respiratory Inhalers Market, 2023 to 2033 Market, with forecasts for product type, drug class, mode of operation, and indication, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the Respiratory Inhalers Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, LA, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Respiratory Inhalers Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Respiratory Inhalers Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Respiratory Inhalers Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Economic Burden of Asthma and Chronic Respiratory Diseases Will Increase Inhaler Demand
3.2.1.2 Inclusion of Inhalers on the WHO Essential Medicines List (EML) and National Reimbursement Lists (NRL) is a Milestone
3.2.1.3 Asthma as an NCD Priority Driving Demand for Inhalers
3.2.1.4 Increased Demand from Emerging Markets
3.2.1.5 The Pharmaceutical Industry is Embracing Digital Technologies to Combat Asthma
3.2.1.6 Improving Quality of Care Through Innovation
3.2.1.7 Increasing Awareness about Respiratory Drugs and Treatments
3.2.2 Market Restraining Factors
3.2.2.1 Inhalers Manufacturing Complications is Hindering the Growth
3.2.2.2 Market Growth Could Be Hindered by High Cost of Respiratory Medications
3.2.2.3 Respiratory Disease Research Efforts and Funding Are Not Aligned with the Relative Disability Related to Respiratory Diseases
3.2.2.4 Approval Process for New Respiratory Inhalers and Drugs is Overseen by Various Regulatory Bodies
3.2.3 Market Opportunities
3.2.3.1 Promising R&D Pipeline in the Respiratory Inhalers
3.2.3.2 An aging population that is prone to respiratory conditions is creating opportunities for manufacturers of inhalers
3.2.3.3 Affordable Care Act: Expanding Medicare Coverage
3.2.3.4 Both Innovator and Generic Products Have Met International Standards Creating Revenue Opportunities
3.2.4 Market Challenges
3.2.4.1 Asthma Inhalers Are Among the Most Complex Pharmaceutical Industry Manufactured Medical Devices in Widespread Use
3.2.4.2 Poor Treatment Adherence
3.2.4.3 Low-Income Countries Face Extra Challenges
3.2.4.4 Disruption of Clinical Trials Due to Pandemic Breakout
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors Impacting Respiratory Drug Delivery Technologies Market
3.5.2 Economic Factors Impacting Respiratory Drug Delivery Technologies Market
3.5.3 Social Factors Impacting Respiratory Drug Delivery Technologies Market
3.5.4 Technological Factors Impacting Respiratory Drug Delivery Technologies Market

4 Respiratory Inhalers Market Analysis by Product Type
4.1 Key Findings
4.2 Product Type Segment: Market Attractiveness Index
4.3 Respiratory Inhalers Market Share by Product Type, 2023 & 2033
4.4 Standard Metered-Dose Inhalers (Standard pMDIs)
4.4.1 Standard pMDIs Market Forecast by Region, 2023-2033 (US$ Bn)
4.4.2 Standard pMDIs Market Share by Region, 2023 & 2033 (%)
4.5 Pressurized Metered-dose Inhalers (pMDI)
4.5.1 pMDI Market Forecast by Region, 2023-2033 (US$ Bn)
4.5.2 pMDI Market Share by Region, 2023 & 2033 (%)
4.6 Metered-Dose Inhaler (MDI) with a Spacer
4.6.1 MDI With Spacer Market Forecast by Region, 2023-2033 (US$ Bn)
4.6.2 MDI With Spacer Market Share by Region, 2023 & 2033 (%)
4.7 Dry Powder Inhalers (DPI)
4.7.1 DPI Market Forecast by Region, 2023-2033 (US$ Bn)
4.7.2 DPI Market Share by Region, 2023 & 2033 (%)
4.8 Soft Mist Inhalers
4.8.1 Soft Mist Inhalers Market Forecast by Region, 2023-2033 (US$ Bn)
4.8.2 Soft Mist Inhalers Market Share by Region, 2023 & 2033 (%)
4.9 Other Inhalation Devices
4.9.1 Other Inhalation Devices Market Forecast by Region, 2023-2033 (US$ Bn)
4.9.2 Other Inhalation Devices Market Share by Region, 2023 & 2033 (%)

5 Respiratory Inhalers Market Analysis by Drug Class
5.1 Key Findings
5.2 Drug Class Segment: Market Attractiveness Index
5.3 Respiratory Inhalers Market Share by Drug Class, 2023 & 2033
5.4 Inhaled Corticosteroid (ICS)
5.4.1 ICS Market Forecast by Region, 2023-2033 (US$ Bn)
5.4.2 ICS Market Share by Region, 2023 & 2033 (%)
5.5 Short-acting beta-agonists (SABA)+ Inhaled Corticosteroid (ICS)
5.5.1 SABA+ICS Market Forecast by Region, 2023-2033 (US$ Bn)
5.5.2 SABA+ICS Market Share by Region, 2023 & 2033 (%)
5.6 Short-acting beta-agonists (SABA)
5.6.1 SABA Market Forecast by Region, 2023-2033 (US$ Bn)
5.6.2 SABA Market Share by Region, 2023 & 2033 (%)
5.7 Long-Acting Beta-Agonist (LABA)
5.7.1 LABA Market Forecast by Region, 2023-2033 (US$ Bn)
5.7.2 LABA Market Share by Region, 2023 & 2033 (%)
5.8 Long-acting muscarinic antagonists (LAMA)
5.8.1 LAMA Market Forecast by Region, 2023-2033 (US$ Bn)
5.8.2 LAMA Market Share by Region, 2023 & 2033 (%)
5.9 Ultra-Long-Acting β-Agonists (ULABA)
5.9.1 ULABA Market Forecast by Region, 2023-2033 (US$ Bn)
5.9.2 ULABA Market Share by Region, 2023 & 2033 (%)
5.10 Short-acting beta-agonists (SABA)+ Short-acting muscarinic-antagonist (SAMA)
5.10.1 SABA+SAMA Market Forecast by Region, 2023-2033 (US$ Bn)
5.10.2 SABA+SAMA Market Share by Region, 2023 & 2033 (%)
5.11 Long-Acting Beta-Agonist (LABA)+ Long-acting muscarinic antagonists (LAMA) + Inhaled Corticosteroid (ICS)
5.11.1 LABA+LAMA+ICS Market Forecast by Region, 2023-2033 (US$ Bn)
5.11.2 LABA+LAMA+ICS Market Share by Region, 2023 & 2033 (%)
5.12 Short-acting muscarinic-antagonist (SAMA)
5.12.1 SAMA Market Forecast by Region, 2023-2033 (US$ Bn)
5.12.2 SAMA Market Share by Region, 2023 & 2033 (%)
5.13 Other Class
5.13.1 Others Market Forecast by Region, 2023-2033 (US$ Bn)
5.13.2 Others Market Share by Region, 2023 & 2033 (%)

6 Respiratory Inhalers Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 Respiratory Inhalers Market Size Estimation and Forecast by Indication
6.4 Asthma
6.4.1 Asthma Market Forecast by Region, 2023-2033 (US$ Bn)
6.4.2 Asthma Market Share by Region, 2023-2033 (%)
6.5 Chronic Obstructive Pulmonary Disease (COPD)
6.5.1 COPD Market Forecast by Region, 2023-2033 (US$ Bn)
6.5.2 COPD Market Share by Region, 2023 & 2033 (%)
6.6 Pulmonary Arterial Hypertension
6.6.1 Pulmonary Arterial Hypertension Market Forecast by Region, 2023-2033 (US$ Bn)
6.6.2 Pulmonary Arterial Hypertension Market Share by Region, 2023 & 2033 (%)
6.7 Other Respiratory Diseases
6.7.1 Other Respiratory Diseases Market Forecast by Region, 2023-2033 (US$ Bn)
6.7.2 Other Respiratory Diseases Market Share by Region, 2023-2033 (%)

7 Respiratory Inhalers Market Analysis by Mode of Operation
7.1 Key Findings
7.2 Mode Of Operation Segment: Market Attractiveness Index
7.3 Respiratory Inhalers Market Share by Mode of Operation, 2023 & 2033
7.4 Manually Operated Inhaler Devices
7.4.1 Manually Operated Inhaler Devices Market Forecast by Region, 2023-2033 (US$ Bn)
7.4.2 Manually Operated Market Share by Region, 2023 & 2033 (%)
7.5 Digitally Operated Inhaler Devices
7.5.1 Digitally Operated Inhaler Devices Market Forecast by Region, 2023-2033 (US$ Bn)
7.5.2 Digitally Operated Inhaler Devices Market Share by Region, 2023 & 2033 (%)
7.6 Other Mode of Operation
7.6.1 Other Mode of Operation Market Forecast by Region, 2023-2033 (US$ Bn)
7.6.2 Other Mode of Operation Market Share by Region, 2023 & 2033 (%)

8 Respiratory Inhalers Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Respiratory Inhalers Market Analysis
9.1 Key Findings
9.2 North America Respiratory Inhalers Market Attractiveness Index
9.3 North America Respiratory Inhalers Market by Country, 2023, 2028 & 2033 (US$ bn)
9.4 North America Respiratory Inhalers Market Size Estimation and Forecast by Country
9.5 North America Respiratory Inhalers Market Volume Estimation and Forecast by Country
9.6 North America Respiratory Inhalers Market Size Estimation and Forecast by Product Type
9.7 North America Respiratory Inhalers Market Size Estimation and Forecast by Drug Class
9.8 North America Respiratory Inhalers Market Size Estimation and Forecast by Mode of Operation
9.9 North America Respiratory Inhalers Market Size Estimation and Forecast by Indication
9.10 U.S. Respiratory Inhalers Market Analysis
9.11 Canada Respiratory Inhalers Market Analysis

10 Europe Respiratory Inhalers Market Analysis
10.1 Key Findings
10.2 Europe Respiratory Inhalers Market Attractiveness Index
10.3 Europe Respiratory Inhalers Market by Country, 2023, 2028 & 2033 (US$ bn)
10.4 Europe Respiratory Inhalers Market Size Estimation and Forecast by Country
10.5 Europe Respiratory Inhalers Market Volume Estimation and Forecast by Country
10.6 Europe Respiratory Inhalers Market Size Estimation and Forecast by Product Type
10.7 Europe Respiratory Inhalers Market Size Estimation and Forecast by Drug Class
10.8 Europe Respiratory Inhalers Market Size Estimation and Forecast by Mode of Operation
10.9 Europe Respiratory Inhalers Market Size Estimation and Forecast by Indication
10.10 Germany Respiratory Inhalers Market Analysis
10.11 UK Respiratory Inhalers Market Analysis
10.12 France Respiratory Inhalers Market Analysis
10.13 Italy Respiratory Inhalers Market Analysis
10.14 Spain Respiratory Inhalers Market Analysis
10.15 Russia Respiratory Inhalers Market Analysis
10.16 Rest of Europe Respiratory Inhalers Market Analysis

11 Asia Pacific Respiratory Inhalers Market Analysis
11.1 Key Findings
11.2 Asia Pacific Respiratory Inhalers Market Attractiveness Index
11.3 Asia Pacific Respiratory Inhalers Market by Country, 2023, 2028 & 2033 (US$ bn)
11.4 Asia Pacific Respiratory Inhalers Market Size Estimation and Forecast by Country
11.5 Asia Pacific Respiratory Inhalers Market Volume Estimation and Forecast by Country
11.6 Asia Pacific Respiratory Inhalers Market Size Estimation and Forecast by Product Type
11.7 Asia Pacific Respiratory Inhalers Market Size Estimation and Forecast by Drug Class
11.8 Asia Pacific Respiratory Inhalers Market Size Estimation and Forecast by Mode of Operation
11.9 Asia Pacific Respiratory Inhalers Market Size Estimation and Forecast by Indication
11.10 Japan Respiratory Inhalers Market Analysis
11.11 China Respiratory Inhalers Market Analysis
11.12 India Respiratory Inhalers Market Analysis
11.13 Australia Respiratory Inhalers Market Analysis
11.14 South Korea Respiratory Inhalers Market Analysis
11.15 Rest of Asia Pacific Respiratory Inhalers Market Analysis

12 Latin America Respiratory Inhalers Market Analysis
12.1 Key Findings
12.2 Latin America Respiratory Inhalers Market Attractiveness Index
12.3 Latin America Respiratory Inhalers Market by Country, 2023, 2028 & 2033 (US$ bn)
12.4 Latin America Respiratory Inhalers Market Size Estimation and Forecast by Country
12.5 Latin America Respiratory Inhalers Market Volume Estimation and Forecast by Country
12.6 Latin America Respiratory Inhalers Market Size Estimation and Forecast by Product Type
12.7 Latin America Respiratory Inhalers Market Size Estimation and Forecast by Drug Class
12.8 Latin America Respiratory Inhalers Market Size Estimation and Forecast by Mode of Operation
12.9 Latin America Respiratory Inhalers Market Size Estimation and Forecast by Indication
12.10 Brazil Respiratory Inhalers Market Analysis
12.11 Mexico Respiratory Inhalers Market Analysis
12.12 Argentina Respiratory Inhalers Market Analysis
12.13 Rest of Latin America Respiratory Inhalers Market Analysis

13 MEA Respiratory Inhalers Market Analysis
13.1 Key Findings
13.2 MEA Respiratory Inhalers Market Attractiveness Index
13.3 MEA Respiratory Inhalers Market by Country, 2023, 2028 & 2033 (US$ bn)
13.4 MEA Respiratory Inhalers Market Size Estimation and Forecast by Country
13.5 MEA Respiratory Inhalers Market Volume Estimation and Forecast by Country
13.6 MEA Respiratory Inhalers Market Size Estimation and Forecast by Product Type
13.7 MEA Respiratory Inhalers Market Size Estimation and Forecast by Drug Class
13.8 MEA Respiratory Inhalers Market Size Estimation and Forecast by Mode of Operation
13.9 MEA Respiratory Inhalers Market Size Estimation and Forecast by Indication
13.10 GCC Respiratory Inhalers Market Analysis
13.11 South Africa Respiratory Inhalers Market Analysis
13.12 Rest of MEA Respiratory Inhalers Market Analysis

14 Company Profiles
14.1 Company Share Analysis
14.2 Strategic Outlook
14.1 GSK plc
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2017-2020
14.1.3.2 Regional Revenue/Market Shares, 2021
14.1.3.3 Segmental Revenue/Market Shares, 2021
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 Koninklijke Philips N.V.
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2017-2021
14.2.3.2 Regional Revenue/Market Shares, 2021
14.2.3.3 Segmental Revenue/Market Shares, 2021
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Boehringer Ingelheim International GmbH
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2017-2021
14.3.3.2 Regional Revenue/Market Shares, 2021
14.3.3.3 Segmental Revenue/Market Shares, 2021
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 3M Health Care
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2017-2021
10.2.1.1 Regional Revenue/Market Shares, 2021
10.2.1.2 Segmental Revenue/Market Shares, 2021
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 AstraZeneca
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2017-2021
14.5.3.2 Regional Revenue/Market Shares, 2021
14.5.3.3 Segmental Revenue/Market Shares, 2021
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Merck & Co., Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2021
14.6.3.2 Regional Revenue/Market Shares, 2021
14.6.3.3 Segmental Revenue/Market Shares, 2021
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Novartis AG
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2017-2021
14.7.3.2 Regional Revenue/Market Shares, 2021
14.7.3.3 Segmental Revenue/Market Shares, 2021
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 OMRON Corporation
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2017-2021
14.8.3.2 Regional Revenue/Market Shares, 2021
14.8.3.3 Segmental Revenue/Market Shares, 2021
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Sunovion Pharmaceuticals Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2017-2021
14.9.3.2 Regional Revenue/Market Shares, 2021
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Teva Pharmaceutical Industries Ltd.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2017-2021
14.10.3.2 Regional Revenue/Market Shares, 2021
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Cipla Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2017-2021
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Recipharm AB
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2017-2021
14.12.3.2 Regional Revenue/Market Shares, 2021
14.12.3.3 Segmental Revenue/Market Shares, 2021
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Medisana GmbH
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 GF Health Products, Inc.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.15 AptarGroup, Inc.
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2017-2021
14.15.3.2 Regional Revenue/Market Shares, 2021
14.15.3.3 Segmental Revenue/Market Shares, 2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from
15.2 Recommendations for Market Players



★調査レポート[世界の呼吸器用吸入器市場2023年～2033年] (コード：VGA23FB021)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の呼吸器用吸入器市場2023年～2033年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のアレルギー性鼻炎薬市場2023年～2033年
  • 世界の喘息＆COPD治療市場2023年～2033年
  • 世界の心血管装置市場2023年～2033年
  • 世界のPoC診断市場2023年～2033年
  • 世界のニューロテックデバイス市場2023年～2033年
  • 世界の神経刺激装置市場2023年～2033年
  • 世界のバイオディフェンス市場2023年～2033年

    • ◆H&Iグローバルリサーチのお客様（例）◆